Ultima Genomics' UG200 Wins Singapore NPM Phase III Sequencing Award
Image
Singapore – November 02, 2026 -- Ultima Genomics' UG200 Sequencing Platform has been selected for the SG-INSIGHT cohort of Phase III of Singapore's National Precision Medicine (NPM) program, which will cover about 450,000 individuals. The company calls it its first major win supporting a national-scale clinical whole genome sequencing initiative. Financial terms were not disclosed.
Phase III targets nearly one in 10 Singapore residents
NPM Phase III is about 4.5 times the size of Phase II, which sequenced 100,000 Singaporeans. The new phase also shifts from healthy individuals to patients across a wide spectrum of health conditions. Participants will come from Singapore's three public healthcare clusters: NHG Health, National University Health System (NUHS) and SingHealth.